Technical Analysis for CSBTF - Kuros Biosciences Ltd

Grade Last Price % Change Price Change
grade B 3.1 39.64% 0.8800
CSBTF closed up 39.64 percent on Wednesday, January 22, 2020, on 73 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical CSBTF trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Narrow Range Bar Range Contraction 39.64%
Wide Bands Range Expansion 39.64%
Gapped Up Strength 39.64%
Narrow Range Bar Range Contraction 465.49%
Wide Bands Range Expansion 465.49%
Older signals for CSBTF ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Kuros Biosciences AG, a biopharmaceutical company, engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases in the United States, the Kingdom of Saudi Arabia, and internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The company's synthetic orthobiologics pipeline products comprise MagnetOs Granules EU and MagnetOs Putty EU for the treatment of orthopedics, spinal, and dental problems; and MagnetOs Granules US and MagnetOs Putty US for the treatment of spinal fusion. Its fibrin/PTH orthobiologics pipeline products include KUR-111, which has completed Phase II clinical trial for the treatment of tibial plateau fractures; KUR-113, which completed Phase II clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase I trial for the treatment of spinal interbody fusion; and KUR-112 that consists of a natural healing matrix combined with a targeted bone growth factor intended to be applied as a single percutaneous injection into solitary bone cysts. The company has collaborations with Checkmate Pharmaceuticals LLC for the licensing of CYT003 for the treatment of oncology; Pfizer Inc. to develop a novel anti-IgE vaccine; and Singapore's Agency for Science, Technology and Research, which researches, develops, and commercializes an influenza vaccine. Kuros Biosciences AG was founded in 2000 and is headquartered in Schlieren, Switzerland.
RTT Biopharmaceutical European Union Influenza Chronic Diseases Biopharmaceutical Products Bone Fractures

Is CSBTF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 3.96
52 Week Low 0.3518
Average Volume 6,878
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 2.5285
10-Day Moving Average 2.1490
Average True Range 0.5814
ADX 20.21
+DI 43.1349
-DI 43.8882
Chandelier Exit (Long, 3 ATRs ) 1.5258
Chandelier Exit (Short, 3 ATRs ) 2.0960
Upper Bollinger Band 4.0589
Lower Bollinger Band 0.9981
Percent B (%b) 0.69
BandWidth 121.0520
MACD Line -0.2904
MACD Signal Line -0.2550
MACD Histogram -0.0354
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.1000
Resistance 3 (R3) 3.1000 3.1000 3.1000
Resistance 2 (R2) 3.1000 3.1000 3.1000 3.1000
Resistance 1 (R1) 3.1000 3.1000 3.1000 3.1000 3.1000
Pivot Point 3.1000 3.1000 3.1000 3.1000 3.1000
Support 1 (S1) 3.1000 3.1000 3.1000 3.1000 3.1000
Support 2 (S2) 3.1000 3.1000 3.1000 3.1000
Support 3 (S3) 3.1000 3.1000 3.1000
Support 4 (S4) 3.1000